FIELD OF THE INVENTION

The present invention relates to a deodorant composition for controlling body odor of localized areas of the body, such as the underarm, or textiles, wherein the composition comprises specific components in particular amounts combined with rhamnolipids for acting specifically on Corynebacterium xerosis.

BACKGROUND OF THE INVENTION

The secretion of eccrine or apocrine sweat glands are odorless. However, it is its degradation by bacteria via enzymatic reactions which produces malodorous compounds.

It is known that the unpleasant odors of perspiration are related in particular to the presence of microorganisms, especially Corynebacterium xerosis.

The compounds which contribute to unpleasant body odor, especially underarm odor, may comprise malodorous steroids, volatile fatty acids, especially aliphatic, branched, saturated and/or unsaturated (C2-C12) fatty acids, and sulfanylalkanol compounds (Natsch, Andreas and Schmid, Joachim and Flachsmann, Felix, Chem. Biodivers., 1 , 1058-1072, (2004)). Certain precursors of odorous substances and mechanisms for generating them are described in the scientific literature [see, for example, Journal of Investigative Dermatology, 130, 529- 540, (2010); Int. J. Cosmet. Sci., 26, 149-156, (2004)].

The function of deodorant active agents is to reduce or prevent the formation of unpleasant odors.

Of the deodorants, the most commonly used are Triclosan (2,4,4'- trichloro-2'-hydroxydiphenylether) and farnesol which involve the drawback of modifying the ecology of skin flora significantly. There are substances that reduce bacterial growth. Of these substances, mention may be made of transition metal chelating agents such as EDTA or DPTA. These materials deprive the environment of the metals required for bacterial growth.

There is therefore a need to find novel ingredients suitable for being integrated in a cosmetic formulation for treating unpleasant body odor associated with human perspiration, particularly underarm odor.

Known basic deodorant compositions generally present more than 1 0% of surfactants. Because of their properties and broad industrial use, they inevitably get into different compartments of the environment, being toxic to many organisms, as demonstrated in several academic publications (e.g. Chem. Rev., 201 1 , 1 1 1 (9), pp 5667-5700).

The need, thus, remains to find novel deodorant active agents which are effective and which do not have above mentioned drawbacks, i.e., deodorant power, antimicrobial activity, it is environmentally-friendly.

It has already been proposed in the patent application WO 2015/091294 a bacteriostatic composition comprising mono-rhamnolipids, wherein its compositions can be used in order to provide bacteriostatic effect to a substrate or as a preservative within the consumer composition. Nevertheless, it does not disclose a specific deodorant composition or any example on how to maintain the anti -microbial activities on the microorganisms responsible for unpleasant body odors, in particular Corynebacterium xerosis, using rhamnolipids in a deodorant, overcoming the drawbacks pointed out above.

SUMMARY OF THE INVENTION

The inventors have surprisingly demonstrated that the particular deodorant formulation comprising:

(a) 0.1 % to 10.0% by weight of rhamnolipids;

(b) 0.01 % to 1 0% by weight of emollients;

(c) 0.01 % to 1 0% by weight of surfactants, preferably nonionic surfactants;

(d) 30% to 99,88% by weight of water,

wherein the ranges are relative to the total weight of the composition , present effective antibacterial activity, with respect to the microorganisms responsible for unpleasant body odors, or textile or leather odors in particular Corynebacterium xerosis, being environmentally friendly for using less surfactants and also being a cost-saving formulation, since the use of further preservatives in the deodorant composition is not mandatory.

The present invention also refers to the method for deodorizing keratinic and textile materials or a leather article and use thereof.

This invention also relates to a method for treating body odor, or a textile material or a leather article, and in particular in the presence of sweat.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1 A, 1 B and 1 C refer to the antimicrobial efficiency assay on Corynbacterium xerosis (ATCC 373 - Positive Gram Bacteria), according to Norm AATCC 147 (qualitative) on a sample comprising 1 % Rhamnolipids (without Aluminum chloride and without preservative).

Figures 2A, 2B and 2C refer to the antimicrobial efficiency assay on Corynbacterium xerosis (ATCC 373 - Positive Gram Bacteria), according to Norm AATCC 147 (qualitative) on a sample treated with Triclosan (concentration 30g/L).

Figures 3A, 3B and 3C refer to the antimicrobial efficiency assay on Corynbacterium xerosis (ATCC 373 - Positive Gram Bacteria), according to Norm AATCC 147 (qualitative) on a sample without treatment (tissue 100% cotton).

Figures 4A, 4B and 4C refer to the antimicrobial efficiency assay on Corynbacterium xerosis (ATCC 373 - Positive Gram Bacteria), according to Norm AATCC 147 (qualitative) on a placebo sample without Aluminum chloride and without preservative.

Figures 5A, 5B and 5C refer to the antimicrobial efficiency assay on Corynbacterium xerosis (ATCC 373 - Positive Gram Bacteria), according to Norm AATCC 147 (qualitative) on a placebo sample comprising Aluminum chloride and without preservative.

DETAILED DESCRIPTION OF THE INVENTION

The foregoing description illustrates and describes the disclosure. Additionally, the disclosure shows and describes only the preferred embodiments but, as mentioned above, it is to be understood that it is capable to use in various other combinations, modifications, and environments and is capable of changes or modifications within the scope of the invention concepts as expressed herein, commensurate with the above teachings and/or the skill or knowledge of the relevant art. The embodiments described herein below are further intended to explain best modes known by applicant and to enable others skilled in the art to utilize the disclosure in such, or other, embodiments and with the various modifications required by the particular applications or uses thereof. Accordingly, the description is not intended to limit the invention to the form disclosed herein. Also, it is intended to the appended claims be construed to include alternative embodiments.

The deodorant compositions of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the present invention described herein, as well as any of the additional or optional ingredients, components, or limitations described herein.

The terms "a," "an," and "the" are understood to encompass the plural as well as the singular.

As used herein, the expression "at least one" means one or more and thus includes individual components as well as mixtures/combinations.

All percentages, parts and ratios are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the specific ingredient level and, therefore, do not include solvents, carriers, by-products, filler or other minor ingredients that may be included in commercially available materials, unless otherwise specified.

All ranges and values disclosed herein are inclusive and combinable. For examples, any value or point described herein that falls within a range described herein can serve as a minimum or maximum value to derive a sub-range, etc.

All publications and patent applications cited in this specification are herein incorporated by reference, and for any and all purposes, as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. In the event of an inconsistency between the present disclosure and any publications or patent application incorporated herein by reference, the present disclosure controls.

"Cosmetically acceptable" means that the item in question is compatible with any keratinous substrate. For example, "cosmetically acceptable carrier" means a carrier that is compatible with any keratinous substrate.

The inventors have surprisingly demonstrated that the particular deodorant formulation comprising rhamnolipids, at least one emollient, at least one surfactant, and water as solvent, in specific amounts, i.e.:

(a) 0.1 % to 10.0% by weight of rhamnolipids;

(b) 0.01 % to 1 0% by weight of emollients;

(c) 0.01 % to 1 0% by weight of surfactants, preferably nonionic surfactants;

(d) 30% to 99,88% by weight of water,

wherein the ranges are relative to the total weight of the composition. The present invention presents effective antibacterial activity, with respect to the microorganisms responsible for unpleasant body and textile or leather odors, in particular Corynebacterium xerosis. In addition, the composition of the present invention is environmentally friendly for using less surfactants and also being a cost-saving formulation, since the use of further preservatives in the deodorant composition is not mandatory, and the rhamnolipids also protects against degradation of the product for a longer shelf life.

DEODORANT COMPOSITION

The deodorant composition of the present invention comprises, in specific amounts, the following essential components: rhamnolipids, at least one emollient, at least one nonionic surfactant and water as solvent, which will be detailed below.

In a preferred embodiment, the deodorant composition claimed herein is an oil-in water emulsion presented in the format of a roll-on, packaged in a device equipped with a ball applicator.

Said specific combination is cost-saving, environmentally friendly and presents an effective microbicidal activity against Corynebacterium xerosis, thus avoiding unpleasant body odors.

The deodorant composition according to the invention preferably has a pH ranging from 3 to 7, preferably between 3.5 and 6.5, and more preferably between 4.0 and 6.0.

In addition, the density of the deodorant composition of the present invention ranges from 1 .0 to 1 .1 5 g/crm ³ , preferably from 1 .08 to 1 .10 g/cm ³ .

Rhamnolipids

Surfactants are generally considered a threat to the aquatic environment since it is responsible for the increase in the solubility of toxic compounds in soils and it is not biodegradable, causing an accumulation in watercourses.

Biosurfactants are a safe alternative and act increasing the surface area of hydrophobic water-insoluble substances which increases the water bioavailability of substances and change the properties of the bacterial cell surface. Besides being a safe and biodegradable alternative for regular surfactants, they are excellent emollients, foaming and dispersing agents.

Rhamnolipids are biosurfactants secreted from Pseudomonas aeruginosa which provide great antibacterial and antifungal activity, which makes them an attractive alternative to chemical surfactants. They have been further proposed in the medical field to combat certain types of bacteria, viruses and fungi.

The rhamnolipids are composed of a glycosyl head group, the rhamnose, and a fatty acid tail, 3-hydroxydecanoic acid. The number of glycosyl head groups defines it as mono or di rhamnolipid.

In a particular embodiment, the at least one rhamnolipid is a rhamnolipid of formula I)

wherein

Ri is selected from the group consisting of H and a-L-rhamnopyranosyl, R2 is selected from the group consisting of H, a C1-C6 linear or branched alkyl, -CH(R ₄ )-CH ₂ -COOH and CH(R )-CH ₂ -COOR ₅ ,

R3 is -(CH2)xCH3, where x is an integer from 4 to 12, preferably x is 6, R ₄ is -(CH2) _y CH3, where y is an integer from 1 to 1 0, preferably y is 4, 6 or 8, and

R5 is a C1-C6 linear or branched alkyl, preferably -CH3,

or their salts, isomers or solvates.

In a preferred embodiment, the at least one rhamnolipid is a mixture of rhamnolipids, in particular a mixture of rhamnolipids of formula (I) as defined above. The mixture of rhamnolipids may in particular comprise a mono-rhamnolipid, a di- rhamnolipid or a combination of both.

In a further preferred embodiment, the deodorant composition essentially comprises mono-rhamnolipid.

The rhamnolipids used in the context of the invention may be used as mixt or highly purified rhamnolipids. A mixt rhamnolipid is a rhamnolipid, having other components as glyceride residues and/or a variety of various rhamnolipid mixtures. Highly purified rhamnolipid is a rhamnolipid whose external impurities have been removed and/or wherein the rhamnolipid have been purified from the other various rhamnolipids present in the crude form.

As well-known from the skilled person, rhamnolipids are secreted by bacteria. Bacteria capable of synthesizing the rhamnolipids used in the context of the present invention can be isolated from oil environments, which have been found to contain bacteria which produce rhamnolipids when the bacteria are grown on either a soluble carbon nutrient source (glucose) or an insoluble carbon nutrient source (glycerol, gas oil). In particular, the rhamnolipids used in the context of the invention may be produced by Pseudomonas aeruginosa.

Accordingly, in a particular embodiment, said at least one rhamnolipid is included in or in the form of a bacterial extract, i.e. is in crude form. Preferably, said at least one rhamnolipid is included in or in the form of a Pseudomonas aeruginosa bacterial extract.

In the context of the invention, the term "bacterial extract" refers both to a set of compounds produced and secreted by a bacterium, thus it is present in the culture medium of the bacterial culture (and therefore in the culture supernatant of the bacterial culture after centrifugation), and a set of compounds comprised in the bacterium, also present in the bacterial pellet of the bacterial culture after centrifugation. Preferably, the bacterial extract refers to the culture medium of the bacterial culture, including compounds secreted by the bacterium.

The inventors demonstrated that the particular deodorant formulations comprising rhamnolipids of the present invention, wherein the rhamnolipids were produced by the Pseudomonas aeruginosa strains LFM634 (ALMEIDA, 201 1 ; Peixoto, 2008; STRELEC, 2006), which belongs to the collection from the Bioproducts Laboratory (Department of Microbiology, ICB, USP); a mutant of P. aeruginosa which was obtained by conjugation and integration of the (ISIacZ / hah) (JACOBS et al., 2003), using the Escherichia coli strain SM10 pir / plT2 (ISIacZ / hah); and the P. aeruginosa ATCC 9027 strain, were particularly efficient in the inhibition of microbial activity, especially on Corynebacterium xerosis.

The rhamnolipids used in the context of the invention may be prepared by any conventional method well-known from the skilled person. The bacterial extract containing the rhamnolipids used in the context of the invention may in particular be obtained from a culture of at least one strain of Pseudomonas aeruginosa.

Conventional methods to prepare rhamnolipids from producing bacteria, in particular to prepare bacterial extracts comprising rhamnolipids, are well-known from the skilled person and typically comprise fermentation, isolation and purification as described in U.S patent 5,455,232 and US 5,466,675, in Santa Anna et al. (2002) Braz. J. Chem. Eng. 19:1 59-1 66 or in Dos Santos et al. (2016) Peer J 4:e2078.

Typically, the bacterium Pseudomonas aeruginosa is cultured in a suitable medium and grown to a desired density. Preferably, the bacterial themselves are removed from the culture media by any method known in the art, such as centrifugation. The supernatant may then be used directly as the crude preparation, or further processing steps well-known from the skilled person may be carried out such as concentration, dehydration, filtration, purification, column chromatography, and the like. Preferably, the final rhamnolipid preparation is not highly purified and corresponds to a crude preparation, preferably and basically comprising mono- rhamnolipids as defined above.

In a particular embodiment, the bacterial extract containing the rhamnolipids used in the context of the invention is obtained by fermenting at least one strain of Pseudomonas aeruginosa, in a culture medium, separating the supernatant comprising the at least one rhamnolipid from the bacterial cells, and optionally at least partially dehydrating, sterilizing, purifying, grinding and/or acylating the bacterial extract thus obtained.

Preferably, the process of preparation of the rhamnolipids used in the context of the invention is carried out so that the rhamnolipids represent 40% to 65% by weight of the total dry matter weight of the bacterial extract.

Accordingly, in a particular embodiment, the at least one rhamnolipid represents 40% to 65% by weight of the total dry matter weight of the bacterial extract, preferably 45% to 60% by weight of the total dry matter weight of the bacterial extract.

As used herein, the term "effective amount" refers to the amount of the rhamnolipid, that, as a whole, enables the formulation being effective against Corynebacterium xerosis.

Preferably, the deodorant composition of the present invention comprises 0.1 % to 1 0.0% by weight of at least one rhamnolipid, in particular at a concentration of 0.2 to 4.0% by weight, preferably 0.5% to 3.0% by weight, more particularly of 0.8 to 2% and even more particularly of 0.9% to 1 .5% by weight compared to the total weight of the composition.

Emollient

The composition of the present invention contains an oil phase comprised of at least one emollient.

Emollients can be used in the formulations in a small amount. The emollients proved suitable for the preparation of the cosmetic deodorants according to the invention are silicone components, plant-derived oils and different esters, which provide a pleasant layer on the skin which enhances feel.

Among the emollients that may be used in the oil-in-water emulsions, it should be mentioned the non-volatile silicone oils plant-derived oils and different esters.

The non-volatile silicone oils are defined in a known way as compounds which are non-volatile at ambient temperature (20-25°C).

Non-volatile silicone oils are defined in a known way as compounds with a low vapor pressure at ambient temperature. Examples of non-volatile silicone oils that may be useful in the present invention include non-volatile polydirmethylsiloxanes (PDMS), polydimethylsiloxanes comprising alkyl or alkoxy groups that are pendent and/or at the end of a silicone chain, these groups each containing from 2 to 24 carbon atoms, phenyl silicones, for instance phenyl trimethicones, phenyl dimethicones, phenyl trimethylsiloxy diphenylsiloxanes, diphenyl dimethicones, diphenyl methyldiphenyl trisiloxanes and 2-phenylethyl trimethylsiloxysilicates, dimethicones or phenyltrimethicones and PPG-1 5 Stearyl Ether. A commercially available dimethicone is sold under the trade name BELSIL® DM 1 00 by Wacker and the PPG-15 Stearyl Ether is sold under the name Arlamol™ PS15E by Croda.

Also, plant-derived oils are those typically extracted from a plant's seeds, although equivalents which can be synthetically manufactured may be employed as well. Suitable plant derived oils include, but are not limited to, soybean oil, jojoba oil, coconut oil, safflower oil, palm kernel oil, cottonseed oil, and pine nut oil.

Among the oil-in-water emollients, mention may also be made to mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate and octyl dodecanol.

In a preferable embodiment, the emollient is a non volatile silicone oil or a mixture of at least two non-volatile silicone, preferably two non-volatile silicone.

In a preferable embodiment, Dimethicone and PPG-1 5 Stearyl Ether are used.

Preferably, the deodorant composition of the present invention comprises 0.01 % to 1 0% by weight of emollient (total content if mixture of emollient is used), in particular at a concentration of 0.1 % to 5.0% by weight, more particularly of 0.5% to 4.5%, even more particularly 3.5 to 4.5% by weight compared to the total weight of the composition.

Surfactants

The deodorant compositions according to the present invention , having oil-and-water phases, preferably comprise one or more surfactants, preferably nonionic surfactants and co-surfactants for the purpose of obtaining a stable emulsion.

Exemplary classes of nonionic surfactants useful herein include, but are not limited to, alkoxylated derivatives of the following: fatty alcohols, alkyl phenols, fatty acids, fatty acid esters and fatty acid amides, wherein the alkyl chain is in the C12-C50 range and having from about 1 to about 1 10 alkoxy groups. The alkoxy groups are selected from the group consisting of C2-C6 oxides and their mixtures, with ethylene oxide, propylene oxide, and their mixtures being the preferred alkoxides. The alkyl chain may be linear, branched, saturated, or unsaturated. Of these alkoxylated non-ionic surfactants, the alkoxylated fatty alcohols are preferred, and the ethoxylated fatty alcohols and propoxylated fatty alcohols are more preferred. The alkoxylated alcohols may be used alone or in mixtures thereof.

Other representative examples of alkoxylated fatty alcohols include ceteareth-33, laureth-3, laureth-23, ceteth-10, steareth-10, steareth-21 , steareth-100, beheneth-5, beheneth-10, and other derivatives and mixtures of the preceding.

Also useful herein as nonionic surfactants are alkyl glycosides, which are the condensation products of long chain alcohols, e.g. C8-C30 alcohols, with sugar or starch polymers. These compounds can be represented by the formula (S)n- O-R wherein S is a sugar moiety such as glucose, fructose, mannose, galactose, and the like; n is an integer of from about 1 to about 1000, and R is a C8-C30 alkyl group. Preferred examples of these surfactants are alkylpolyglucosides wherein S is a glucose moiety, R is a C8-C20 alkyl group, and n is an integer of from about 1 to about 9. Commercially available examples of these surfactants include decyl polyglucoside and lauryl polyglucoside, all the above-identified polyglucosides APG® are available from Cognis, Ambler, Pa. Also useful herein are sucrose ester surfactants such as sucrose cocoate and sucrose laurate.

Other nonionic surfactants suitable for use in the present invention are glyceryl esters and polyglyceryl esters, including but not limited to, glyceryl monoesters, preferably glyceryl monoesters of C16-C22 saturated, unsaturated and branched chain fatty acids such as glyceryl oleate, glyceryl monostearate, glyceryl monoisostearate, glyceryl monopalmitate, glyceryl monobehenate, and mixtures thereof, and polyglyceryl esters of C16-C22 saturated, unsaturated and branched chain fatty acids, such as polyglyceryl-4 isostearate, polyglyceryl-3 oleate, polyglyceryl-2 sesquioleate, triglyceryl diisostearate, diglyceryl monooleate, tetraglyceryl monooleate, and mixtures thereof.

Also useful herein as nonionic surfactants are sorbitan esters. Preferable are sorbitan esters of C16-C22 saturated, unsaturated and branched chain fatty acids. These sorbitan esters usually comprise mixtures of mono-, di-, tri-, etc. esters. Representative examples of suitable sorbitan esters include sorbitan monooleate, sorbitan sesquioleate, sorbitan monoisostearate, sorbitan stearates, sorbitan trioleate, sorbitan tristearate, sorbitan dipalmitates, and sorbitan isostearate. Also suitable for use herein are alkoxylated derivatives of glyceryl esters, sorbitan esters, and alkyl polyglycosides, wherein the alkoxy groups is selected from the group consisting of C2-C6 oxides and their mixtures, with ethoxylated or propoxylated derivatives of these materials being the preferred. Nonlimiting examples of commercially available ethoxylated materials include polysorbate materials sold under the tradename of TWEEN® by Croda, Inc. (ethoxylated sorbitan mono-, di- and/or tri-esters of C12 to C18 fatty acids with an average degree of ethoxylation of from about 2 to about 20).

Another suitable nonionic surfactant is an alkoxylated alcohol of glyceryl esters such as the polyethylene glycol derivative of hydrogenated castor oil, PEG-40 hydrogenated castor oil.

The nonionic surfactants may be chosen, for example, from polyethoxylated and/or polypropoxylated alkyl phenols, alpha-diols and alcohols, comprising fatty chains comprising, for example, from 8 to 1 8 carbon atoms, and the number of ethylene oxide and/or propylene oxide groups may range from 2 to 50. The non-ionic surfactant may be chosen, for example, from copolymers of ethylene oxide and of propylene oxide, condensates of ethylene oxide and/or of propylene oxide with fatty alcohols or polyoxypropylene/polyoxyethylene ethers of fatty alcohol; polyethoxylated fatty amides comprising, for example, from 2 to 30 moles of ethylene oxide, polyglycerolated fatty amides comprising on average 1 to 5, and, for example, 1 .5 to 4, glycerol groups; polyethoxylated fatty amines comprising, for example, from 2 to 30 moles of ethylene oxide, N-alkylglucamine derivatives, and amine oxides such as (C10-C14)alkyl amine oxides and N-acylaminopropylmorpholine oxides.

Suitable examples of nonionic surfactants for use in the invention are fatty alcohols such as cetearyl alcohol, stearyl alcohol, cetyl alcohol, lauryl alcohol, behenyl alcohol, polysorbate compounds and derivatives such as polysorbate-21 and polysorbate-20, PEG-40 hydrogenated castor oil, PPG-5-Ceteth-20, alkylpolyglucosides such as caprylyl/capryl glucoside and decyl glucosides, and mixtures thereof.

The topical compositions according to the present invention furthermore advantageously contain at least one co-surfactant such as fatty alcohols, selected from the group consisting of cetyl alcohol, stearyl alcohol, cetearyl, behenyl alcohol and the like and glyceryl stearate.

In a preferred embodiment the non-ionic surfactants used in the present invention is Ceteareth-33 (sold under the trade name Sinnowax® AO by BASF, and Steareth-21 ) and the co-surfactant is Cetearyl Alcohol (sold under the trade name HallStar® TA-161 8 by HallStar).

The choice of the nonionic surfactant(s), having specific hydrophilic- lipophilic balance (HLB) will depend on the desired properties of the oily phase, which is a matter of routine operation for a person skilled in the art to adjust the nature of the surfactants present in the compositions in accordance with the invention such that the desired cosmetic properties and stability properties thereof are not thereby affected.

Preferably, the deodorant composition of the present invention comprises 0.01 % to 10% by weight of surfactants other than rhamnolipids, in particular at a concentration of 0.2% to 8% by weight, more particularly of 0.3% to 5.0% by weight compared to the total weight of the composition.

Solvent

The liquid solvent vehicle for use in the deodorant composition of the present invention a cosmetically acceptable solvent, wherein the solvent is preferably water. It is used to assist in incorporating dry materials into the deodorant.

Furthermore, the solvent can also be water-soluble or miscible solvents and/or their mixture and/or a mixture of one or more of them with water.. The water- soluble or miscible solvents may comprise short-chain mono-alcohols for example C1 -C4 such as ethanol, isopropanol; diols or polyols such as ethyleneglycol, 1 ,2- propyleneglycol, 1 ,3-butylene glycol, hexyleneglycol, diethyleneglycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monomethylether, triethylene glycol monomethylether and sorbitol. Propyleneglycol and glycerin, propane 1 ,3 diol shall more particularly be used, afone, as mixtures and/or as mixtures with water.

Preferably, the deodorant composition of the present invention comprises 30 to 99.88% by weight of solvent, in particular at a concentration of 40% to 95% by weight, more particularly of 60% to 95% by weight compared to the total weight of the composition.

Optional Components

In addition to the essential components described hereinbefore, the deodorant compositions of the present invention may further comprise one or more optional components which may modify the physical or chemical characteristics of the compositions or serve as additional "active" components when deposited on the skin, provided that the optional components are physically and chemically compatible with the essential components described herein, or do not otherwise unduly impair product stability, aesthetics, or performance.

Non-limiting examples of such optional materials include components such as pH buffering agents; additional malodor controlling agents such as antiperspirant actives (preferably chosen from aluminum and/or zirconium salts; complexes of zirconium chlorohydrate and of aluminum chlorohydrate with an amino acid); fragrance materials; wax; humectants; soothing agents; dyes and pigments; and related materials; preservatives; and soothing agents.

Of course, a person skilled in the art will take care to choose these optional additional compounds and/or their amounts in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, detrimentally affected by the envisioned addition.

Implementation of the present disclosure is provided by way of the following examples. The examples serve to illustrate the technology without being limiting in nature.

EXAMPLES

Method of preparation

The compositions of the present invention were prepared according to the following method: 1 . Adding of the entire oil phase in a manufacture vessel having high speed turbine and helix;

2. Increasing the temperature to 65 °C for total melting of solid components;

3. Slowly adding the water under vigorous stirring to form the emulsion;

4. Cooling to 45 °C and adding of the active compounds.

Antimicrobial test on Corynebacterium xerosis

The inventors proceeded with the antimicrobial tests, according to the

AATCC 147 standard, wherein the formation of inhibition zones for Corynebacterium xerosis (ATCC 373) were evaluated.

It was compared five samples in triplicate for comparative purposes: the deodorant roll-on composition according to the present invention having rhamnolipids; a deodorant roll-on composition having Triclosan (30 g/mL); a standard deodorant roll-on composition without microbial actives; a Placebo (1 ) without the antiperspirant active and preservative; and a Placebo (2) without preservative, as can be seen on Table 1 . The values are described in %.

Table 1 - Examples

Inventive Positive Negative

Ingredient Placebo 1 Placebo 2 composition control control

(INCI name) (Fig. 4) (Fig. 5)

(Fig. 1) (Fig- 2) (Fig- 3)

Aluminum

15 1 5 Chlorohydrate

lodopropynyl

Butylcarbamat 0.075

e

Dimethicone 0.5 0.5 0.5 0.5

Water qs qs qs qs qs

Cetearyl

2.5 2.5 2.5 2.5 Alcohol

Ceteareth-33 1 .25 1 .25 1 .25 1 .25

PPG-15

3 3 3 3 Stearyl Ether Inventive Positive Negative

Ingredient Placebo 1 Placebo 2 composition control control

(INCI name) (Fig. 4) (Fig. 5)

(Fig. 1) (Fig. 2) (Fig. 3)

Rhamnolipids 1

Triclosan (30

0.3

g/mL)

The rhamnolipids concentration (1 %) is based on said compound in a pure state, produced by Pseudomonas aeruginosa strains of Table 2.

Table 2 - Pseudomonas aeroginosa strains used in the present invention

Strains

LFM634

ATCC 9027

Mutant of P. aeruginosa which was obtained by conjugation and integration of the (ISIacZ / hah) The compositions were embedded on a fabric, which was placed on a culture medium (Brain Heart Infusion Agar - B.H. I), previously sterilized by U.V. light. After inoculating the bacteria Corynebacterium xerosis on the Petri dish having the culture medium and compositions as previously defined, it was incubated during 48 hours, and then the inhibition zone, if formed, was analyzed.

The inhibition zone determines the antimicrobial activity, which was calculated with the following formula (if formed):

W = (T - D)/2

wherein

W = Clear Area of Inhibition Size in mm.

T = Total diameter of the test sample plus the clear zone of inhibition in mm.

D = Diameter of the test sample.

The tests results can be seen on Table 3 and Figures 1 to 5.

The antimicrobial tests on the deodorant samples, according to the present invention showed that there was no bacterial growth above the fabric triplicates and there was the formation of an inhibition area, indicating that the formulation containing the rhamnolipid was able to prevent the bacterial growth around the fabric area.

As a negative control, the same formulation with and without aluminum chloride was used to demonstrate that there was no inhibition area zone formation. This indicates that neither the formulation itself nor just the aluminum chloride would be able to prevent the microbial growth.

In order to prove the antimicrobial activity of the rhamnolipid, a positive control of the same formulation containing Triclosan was used to perform the same test. This positive control showed the inhibition area formation, just as the rhamnolipid.

Table 3 - Antimicrobial test results

While particular embodiments of the invention have been shown and described, various modifications will be apparent to those skilled in the art, and therefore it is not intended that the invention be limited to the disclosed embodiments or to details thereof, and departures may be made therefrom within the spirit and scope of the invention.